LncRNA HAND2-AS1 represses cervical cancer progression by interaction with transcription factor E2F4 at the promoter of C16orf74.
Adult
Aged
Animals
Binding Sites
Carcinogenesis
/ genetics
Cell Line, Tumor
Cell Movement
/ genetics
Cell Proliferation
/ genetics
Disease Progression
Down-Regulation
/ genetics
E2F4 Transcription Factor
/ metabolism
Female
Gene Expression Regulation, Neoplastic
Humans
Intercellular Signaling Peptides and Proteins
/ genetics
Mice, Inbred BALB C
Mice, Nude
Middle Aged
Models, Biological
Neoplasm Invasiveness
Promoter Regions, Genetic
Proteins
/ metabolism
RNA, Long Noncoding
/ genetics
Uterine Cervical Neoplasms
/ genetics
C16orf74
E2F4
HAND2-AS1
cervical cancer
invasion
migration
proliferation
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
14
05
2019
revised:
08
02
2020
accepted:
15
02
2020
pubmed:
22
4
2020
medline:
29
4
2021
entrez:
22
4
2020
Statut:
ppublish
Résumé
Cervical cancer is one of the major malignancies, the pathophysiology and progression of which remain to be scarcely understood. Long non-coding RNAs (lncRNAs) have been previously implicated in the progression of cervical cancer. Here, the purpose of this study was to identify whether lncRNA heart- and neural crest derivative-expressed 2-antisense RNA 1 (HAND2-AS1) affect the development of cervical cancer through regulation of chromosome 16 open reading frame 74 (C16orf74) by mediating a transcription factor E2F4. RT-qPCR was performed to determine the expression of HAND2-AS1 in cervical cancer cells. Then, cervical cancer cells were treated with HAND2-AS1 or si-E2F4 RNA, or C16orf74, after which the proliferation, colony formation, migration and invasion were detected. Moreover, the binding between HAND2-AS1 and E2F4 or between E2F4 and C16orf74 was explored. Finally, the tumorigenesis of cervical cancer cells was measured in nude mice with altered HAND2-AS1/E2F4/C16orf74 expression. HAND2-AS1 exhibited poor expression in cervical cancer, and HAND2-AS1 overexpression suppressed the proliferation, colony formation, migration and invasion of cervical cancer cells. In addition, HAND2-AS1 was found to recruit transcription factor E2F4 to C16orf74 promoter region and down-regulate C16orf74 expression. Lastly, HAND2-AS1/E2F4/C16orf74 modulated the tumorigenesis of cervical cancer in nude mice. In conclusion, this study provided evidence on the inhibitory effect of HAND2-AS1 on the development of cervical cancer through the suppression of C16orf74 expression by recruiting transcription factor E2F4. This study highlights the potential of lncRNA HAND2-AS1 as a target in the treatment of cervical cancer.
Identifiants
pubmed: 32314545
doi: 10.1111/jcmm.15117
pmc: PMC7294116
doi:
Substances chimiques
C16ORF74 protein, human
0
E2F4 Transcription Factor
0
Intercellular Signaling Peptides and Proteins
0
Proteins
0
RNA, Long Noncoding
0
long non-coding RNA HAND2-AS1, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6015-6027Informations de copyright
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
J Cell Biochem. 2019 Jun;120(6):9564-9571
pubmed: 30520131
Tumour Biol. 2016 Jun;37(6):7213-27
pubmed: 26666817
Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):2103-2111
pubmed: 30915755
BMC Cancer. 2019 Jan 30;19(1):111
pubmed: 30700274
PLoS One. 2010 Dec 21;5(12):e15260
pubmed: 21203532
Oncotarget. 2016 Jul 28;8(31):50460-50475
pubmed: 28881575
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1848-1853
pubmed: 30078677
PLoS One. 2019 Apr 18;14(4):e0215250
pubmed: 30998706
Mol Cancer Ther. 2020 Jan;19(1):187-198
pubmed: 31597713
Leukemia. 2012 Oct;26(10):2277-85
pubmed: 22475873
Mod Pathol. 2013 Feb;26(2):155-65
pubmed: 22996375
Biosci Rep. 2018 Dec 21;38(6):
pubmed: 30487158
Acta Cytol. 2019;63(3):206-214
pubmed: 30947186
Cancer Cell Int. 2019 Mar 14;19:58
pubmed: 30923460
Biomed Pharmacother. 2017 Jan;85:511-516
pubmed: 27899255
J Photochem Photobiol B. 2016 Aug;161:368-74
pubmed: 27295416
Exp Ther Med. 2019 Oct;18(4):2512-2518
pubmed: 31555362
J Cell Physiol. 2019 Aug;234(10):17494-17504
pubmed: 30912129
Biochem Biophys Res Commun. 2019 Jun 4;513(3):669-674
pubmed: 30982576
Gynecol Oncol. 2018 Jan;148(1):132-138
pubmed: 29089122
J Cell Mol Med. 2020 Jun;24(11):6015-6027
pubmed: 32314545
J Cell Physiol. 2009 Nov;221(2):350-8
pubmed: 19562678
Int J Gynecol Cancer. 2014 Sep;24(7):1140-5
pubmed: 25078335
PLoS One. 2018 Jul 18;13(7):e0200717
pubmed: 30020984
Oncotarget. 2017 May 18;8(42):71881-71893
pubmed: 29069754
Head Neck. 2018 Jul;40(7):1555-1564
pubmed: 29575229
Cancer Lett. 2018 Jan 28;413:23-34
pubmed: 29107108
Oncotarget. 2017 Oct 19;8(69):113662-113672
pubmed: 29371937
Biochem Biophys Res Commun. 2019 May 21;513(1):56-63
pubmed: 30935691
PLoS One. 2016 Apr 26;11(4):e0153274
pubmed: 27115350
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
Gynecol Oncol. 2017 Aug;146(2):438-439
pubmed: 28576262
Biosci Rep. 2019 Jan 11;39(1):
pubmed: 30509963
BMC Bioinformatics. 2006 Oct 23;7:469
pubmed: 17059609
Cell Death Dis. 2018 Feb 14;9(2):238
pubmed: 29445179